showed that anti‐PD1 treatment in breast cancer triggers the clonal expansion of CD4+ T cell subsets expressing Th1 markers like IFNG, alongside Tfh cell markers such as BCL6 and CXCR597. This evidence concerns the gene PDCD1 and breast carcinoma.